H. Kurata

发表

Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992

Amanda M. Duran, Anna L. Blobaum, J. Meiler, 2018, Molecular Pharmacology.

Efficacy and immunomodulatory actions of ONO‐4641, a novel selective agonist for sphingosine 1‐phosphate receptors 1 and 5, in preclinical models of multiple sclerosis

M. Imai, S. Nakade, K. Sato, 2013, Clinical and experimental immunology.

Therapeutic Effects of Novel Sphingosine-1-Phosphate Receptor Agonist W-061 in Murine DSS Colitis

T. Mizushima, Toshinori Ito, J. Nishimura, 2011, PloS one.

Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.

C. Lindsley, Hyekyung P. Cho, P. Conn, 2015, Bioorganic & medicinal chemistry letters.

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases.

T. Kondo, S. Nakade, H. Habashita, 2017, Journal of medicinal chemistry.

Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives.

K. Shinozaki, T. Matsushita, A. Naganawa, 2016, Bioorganic & medicinal chemistry letters.

Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives.

K. Shinozaki, T. Matsushita, A. Naganawa, 2015, Bioorganic & medicinal chemistry letters.

Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.

K. Shinozaki, T. Matsushita, T. Kanaji, 2015, Bioorganic & medicinal chemistry letters.

Preventive and Therapeutic Efficacy of ONO-4641, a Selective Agonist for Sphingosine 1-Phosphate Receptor 1 and 5, in Preclinical Models of Type 1 Diabetes Mellitus.

S. Nakade, H. Habashita, Kenji Hiraizumi, 2021, Biological & pharmaceutical bulletin.

Structure-activity relationship studies of S1P agonists with a dihydronaphthalene scaffold.

M. Minami, S. Nakade, H. Habashita, 2012, Bioorganic & medicinal chemistry letters.

Discovery of S1P agonists with a dihydronaphthalene scaffold.

M. Minami, S. Nakade, H. Habashita, 2011, Bioorganic & medicinal chemistry letters.

Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249.

C. Lindsley, Takahiro Mori, D. Engers, 2019, Bioorganic & medicinal chemistry letters.

ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels.

Anna L. Blobaum, J. Meiler, C. Lindsley, 2016, ACS chemical neuroscience.

Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1

Yasuyuki Kihara, Raymond C. Stevens, Caroline Rodgers, 2015, Cell.

Combined NK1 and NK2 tachykinin receptor antagonists: synthesis and structure-activity relationships of novel oxazolidine analogues.

T. Nishi, T. Fukazawa, H. Kurata, 1999, Bioorganic & medicinal chemistry letters.

Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation.

Toshinori Ito, H. Mizuno, Jinghai Song, 2012, Transplant immunology.

Structure-activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety.

M. Minami, S. Nakade, H. Habashita, 2011, Bioorganic & medicinal chemistry letters.

Efficacy and immunomodulatory actions of ONO‐4641, a novel selective agonist for sphingosine 1‐phosphate receptors 1 and 5, in preclinical models of multiple sclerosis

S. Nakade, K. Sato, H. Habashita, 2013, Clinical and experimental immunology.